Skip to main content
Download PDF

Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people

BMC Infectious Diseases volume 22, Article number: 889 (2022) Cite this article

Abstract

Background

Our study examines if SARS-CoV-2 infections varied by vaccination status, if an individual had previously tested positive and by neighbourhood socioeconomic deprivation across the Delta and Omicron epidemic waves of SARS-CoV-2.

Methods

Population cohort study using electronic health records for 2.7 M residents in Cheshire and Merseyside, England (3rd June 2021 to 1st March 2022). Our outcome variable was registered positive test for SARS-CoV-2. Explanatory variables were vaccination status, previous registered positive test and neighbourhood socioeconomic deprivation. Cox regression models were used to analyse associations.

Results

Originally higher SARS-CoV-2 rates in the most socioeconomically deprived neighbourhoods changed to being higher in the least deprived neighbourhoods from the 1st September 2021, and were inconsistent during the Omicron wave. Individuals who were fully vaccinated (two doses) were associated with fewer registered positive tests (e.g., individuals engaged in testing between 1st September and 27th November 2021—Hazards Ratio (HR) = 0.48, 95% Confidence Intervals (CIs) = 0.47–0.50. Individuals with a previous registered positive test were also less likely to have a registered positive test (e.g., individuals engaged in testing between 1st September and 27th November 2021—HR = 0.16, 95% CIs = 0.15–0.18. However, the Omicron period saw smaller effect sizes for both vaccination status and previous registered positive test.

Conclusions

Changing patterns of SARS-CoV-2 infections during the Delta and Omicron waves reveals a dynamic pandemic that continues to affect diverse communities in sometimes unexpected ways.

Peer Review reports

Background

Vaccination is the cornerstone of preventing severe COVID-19 disease among individuals infected with the SARS-CoV-2 virus [1]. Vaccines have also provided some protection from becoming infected with SARS-CoV-2, as has prior infection [2,3,4]. Unvaccinated individuals are at higher risk of severe illness, hospitalisation or death from COVID-19 [4, 5]. There is a lack of evidence over how long either vaccine- or infection-acquired immunity to SARS-CoV-2 infection and COVID-19 disease may last for [6]. Concerns over waning immunity [7, 8], and immune escape with the Omicron variant [9], led to the introduction of ‘booster’ vaccination programmes in late 2021 [10]. In addition to loss of biological protection, the risk behaviours of individuals change over time and may be influenced by feeling protected by vaccination or prior infection for longer than they actually are [11, 12]. Modelling of seasonal influenza vaccination programmes suggests that such behaviour changes can offset the effectiveness of vaccination programmes [13].

The COVID-19 pandemic has reinforced and amplified existing social inequalities in health. The number of infections, hospitalisations and deaths due to COVID-19 were disproportionally higher among residents of socioeconomically deprived neighbourhoods [14,15,16]. Vaccination uptake was also lower among deprived populations [17]. Assessing the importance of vaccine- and infection-acquired immunity are therefore social issues. However, current debates and evaluations of these issues largely ignore this social dimension. For example, estimates of vaccine effectiveness at reducing infections often present only unadjusted associations [18], which does not account for the differing levels of exposure to SARS-CoV-2 and vaccine uptake among different population and social groups.

The aim of this study is to examine if SARS-CoV-2 infections in England varied by vaccination status, if an individual had previously tested positive and by neighbourhood socioeconomic deprivation. We compare experiences during the epidemic curves of two SARS-CoV-2 variants: Delta and Omicron. The periods where these variants dominate infections represent an interesting case study due to high number of infections, high vaccine uptake, limited non-pharmaceutical interventions and changing public responses to national COVID-19 measures. It is also a period where all residents of England had access to free SARS-CoV-2 testing, allowing us to leverage electronic health records linked to testing records.

Methods

Data source

Data were accessed from the Combined Intelligence for Population Health Action (CIPHA; www.cipha.nhs.uk) resource. CIPHA is a population health management data resource set up to support responses to COVID-19. It constitutes linked electronic health records from routinely collected administrative data. Here, we used the population spine for CIPHA (all people registered with a GP and their primary care records), linked to NHS vaccination records and all registered SARS-CoV-2 tests.

Study population

CIPHA contains linked pseudonymised electronic health care records for 2,864,997 people. We included people (n = 2,767,027) with a complete address who were resident during the study period in the integrated care region the CIPHA resource was set up to serve (Cheshire and Merseyside, England). Participants with missing data (n = 101) were excluded from analyses (other than missing data for ethnicity which we adjust for). For each period of analysis, we only include people who were alive up to the end of the period to minimise issues with immortal time bias.

Study design

We selected three time periods to analyse:

  1. 1.

    Delta—3rd June to 1st September 2021 We defined the start of the period as when Public Health England (now UK Health Security Agency) stated that the Delta variant was 99% of all infections [19].

  2. 2.

    Delta—1st September to 27th November 2021 We selected this period to cover the wave of infections associated with the new school year (starting 1st September 2021) up to where the first case of Omicron was detected in England. The latter period was selected to focus our analyses on cases relating primarily to the Delta variant of SARS-CoV-2 to avoid any differences in risk of further infection or vaccine escape the Omicron variant may have.

  3. 3.

    Omicron—13th December 2021 to 1st March 2022 We defined the start of this period as when sequencing data suggested that most positive tests were for Omicron. The period is then up to the end of available data at the time of analysis.

Outcome variable

The primary outcome variable was time to SARS-CoV-2 infection (registered positive test) during each period. Time was defined as when the test was taken rather than when it was processed. Positive cases are compiled from data feeds supplied by the UK Health Security Agency, who share all Pillar 1 (tests in care settings) and Pillar 2 (tests in the community) positive tests which are linked within CIPHA. Positive cases are identified using both lateral flow and polymerase chain reaction (PCR) tests.

Explanatory variables

We focused on three key explanatory variables: COVID-19 vaccination status, previous SARS-CoV-2 infection and neighbourhood socioeconomic deprivation.

Vaccination status was defined as the number of doses (of any vaccine type combination e.g. BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca)) an individual had received (0–3). We identified the number of first doses received two weeks before the start of each period, and one week prior for two or three doses, which we define as the time to receive immune protection (following other research [3, 8]). The measure was then updated (i.e., time-varying) over time to account for people who received an additional vaccination during each study period. This was achieved using established methods through updating the time interval based on vaccination status, holding other covariates constant [20].

Previous SARS-CoV-2 infection (binary) was defined as whether an individual had a registered positive test from the start of the pandemic up to two weeks before the start of each period [21]. The measure was held constant and not time varying. We defined this two-week period as the time to develop immune protection. Infections were selected based on the first positive test, and subsequent positive tests occurring more than 90 days apart (which we defined as a further/subsequent infections). This definition follows established research elsewhere [8, 21]. We evaluated if this definition affected our results by introducing immortal time bias (i.e., some individuals could not test positive for parts of the study periods if they tested positive closer to the start period) through only including individuals who had a previous positive test at least 90 days before the start of the period as a sensitivity analysis.

Neighbourhood socioeconomic deprivation was measured through matching individual’s residence to the 2019 Index of Multiple Deprivation (IMD) [22]. The IMD is a multi-dimensional index of neighbourhood deprivation, based on seven weighted domains including income, employment, education and health. The IMD score is measured for Lower Super Output Areas (LSOAs) which are small zones representing neighbourhoods (~ 1500 people). Larger scores represent higher levels of socioeconomic deprivation. We also reported analyses by IMD decile to aid interpretation.

Control variables

We accounted for demographic factors sex (male or female) and age. Age was included as a categorical variable to account for non-linear dynamics and produced a better fitting model than a continuous measure. Age is an important factor for different risks in exposure to SARS-CoV-2, as well as to reflect that the vaccination programme was rolled out by age group. Ethnicity was included to account for inequalities in both exposure to SARS-CoV-2 and vaccination uptake. Broad ethnic groups were used: White, Asian, Black, Mixed and Other. We also include ‘prefer not to say / missing’ as a category in our models, since they accounted for a large proportion of records and this can account for any issues with this group being different in causal behaviours. Health status was included to account for differences in behaviours, where people with long-term health conditions may ‘shield’ or minimise social contacts. We define health status (comorbidity) as if individuals had a registered Expanded Diagnosis Clusters codes (yes or no). Codes represent diseases, symptoms or conditions that are treated in ambulatory and inpatient hospital settings. Finally, we also adjusted for differences in testing dynamics by accounting for whether an individual had registered a negative test in the previous month.

Statistical analyses

We found evidence of inequalities in registered test behaviours (Additional file 1: Table A). To minimise this potential bias in our regression analyses, we focused our analyses on two cohorts. First, we selected only individuals who reported a negative test in the month prior to each time period as a proxy for being engaged in testing. This is similar to a ‘test-negative’ study design which have been used for studying vaccine effectiveness [23]. Second, we analysed individuals who had received an influenza vaccine within a year of each time period as a proxy of being engaged in healthcare (i.e., likely to register a test even if unvaccinated and not disengaged with health care) [24]. For the Omicron period, we extended this time frame to 1st September 2020 to fully capture the previous year’s influenza vaccination campaign. While our main models use all individuals, in a sensitivity analysis we restricted this population to just people aged 65 years and over as they are the focus of the UK influenza vaccination programme. Matching methods were also investigated for balancing populations across our exposure variables, but did not significantly alter the models and are not discussed here. We also reported analyses for all residents of Cheshire and Merseyside as a sensitivity analysis.

Descriptive statistics and visualisations were produced to summarise our data and identify key trends. Cox regression models were then used to predict the associations between our explanatory and control variables to our outcome variable (time to registered positive test). Hazard ratios and 95% confidence intervals were estimated from these models to summarise associations. Interaction effects for vaccine status and previous infection were tested, but not included in the results since they did not improve the model fit. We also stratified analyses by 10-year age group. This was to capture dynamics between children/adolescents and adults which will each have different modes of transmissions, risks and vaccination access [25]. We tested the proportional hazards assumption of models through estimating Schoenfeld residuals. Most associations met the proportional hazards assumption. Where the assumption was violated, estimates were not extreme and/or resulting plots did not display obvious violations suggesting that findings were potentially exaggerated by our large sample sizes. Alternative model specifications did not produce significantly different findings.

Patient and public involvement

No patients and the public were involved in this piece of research.

Results

Table 1 presents the descriptive characteristics of our cohort. Figure 1 presents trends in registered positive cases for all residents since the start of the pandemic to contextualise our three periods. The number of cases was high during both Delta periods compared to previous waves. Omicron saw large growth in cases (10.5% of all residents registered a positive test; more than twice as high as both Delta periods) from new infections and the emergence of subsequent infections that almost reach the levels of new infections during the two Delta periods. We estimated that 11.4% of positive tests during the Omicron period were subsequent positive tests (in the other two periods, this figure was < 1%). In particular, incidence of further infections were roughly twice as high in the most deprived compared to least deprived areas (Fig. 2). Percentage of people with registered positive tests across our exposure variables are described in Additional file 1: Table B.

Table 1 Sample characteristics for each period. Note: Values are frequency counts (percentage) unless specified
Full size table
Fig. 1
figure 1

Seven day moving average for registered positive tests for all residents in Cheshire and Merseyside (England) by whether it was an individual’s first registered positive test (new infection) or further/subsequent positive test. A = Total number of cases, B = Total number of cases per 100,000 population

Full size image
Fig. 2
figure 2

Seven day moving average for the percentage of all registered positive tests that were identified as a subsequent infection (≥ 2nd positive registered test more than 90 days apart) by decile of deprivation (3rd June 2021–2nd February 2022). Note: 1 = most deprived decile, 10 = least deprived decile, other deciles set to low transparency to minimise distraction

Full size image

Tables 2 (individuals engaged in testing) and 3 (individuals engaged in healthcare) presents findings from a series of Cox regression models predicting factors associated with time to registered positive test. There was agreement in associations across both model types for the two Delta periods, with less consistent findings for the Omicron period.

Table 2 Results for a Cox regression predicting time to a registered positive test for individuals who had registered a negative lateral flow test within a month of the time period start date (as a proxy for testing engaged)
Full size table

Unadjusted associations for both Delta waves showed that people who were vaccinated had lower likelihoods of registered positive test for SARS-CoV-2. For instance, in individuals engaged in testing we estimated that people who were fully vaccinated (2 doses) were 60% (Hazard Ratio (HR) = 0.40, 95% Confidence Intervals (CIs) = 0.39–0.42) and 52% (HR = 0.48, 95% CIs = 0.47–0.50) less likely to have a registered positive test in the first and second Delta waves respectively compared to unvaccinated people. In individuals engaged in healthcare, we estimated a larger effect size with individuals who were fully vaccinated being 63% (HR = 0.37, 95% CIs = 0.36–0.39) and 66% (HR = 0.34, 95% CIs = 0.33–0.34) less likely to have a registered positive test in the first and second Delta waves respectively compared to unvaccinated people. After adjusting for other demographic and social factors that may affect exposure to the virus, the strength of associations reduced but remained negatively associated (i.e., HR < 1 and 95% CIs did not cross 1). In the second Delta wave (1st September to 27th November 2021), we observed a stronger protective effect in people who had received 3 doses in both models (i.e., fully vaccinated and ‘boosted’).

Associations during the Omicron period were different to the previous Delta periods and varied between models. For both models, unadjusted associations suggested positive associations in one or two doses, and a negative association for three doses (both compared to unvaccinated populations). For example, individuals engaged in testing with three doses were 14% less likely (HR = 0.86, 95% CIs = 0.84–0.89) and individuals who were healthcare engaged were 23% less likely (HR = 0.77, 95% CIs = 0.75–0.78). In adjusted models, negative associations for three doses remained in both models although effect sizes were smaller. This suggests that following adjustment for known risk factors that may affect exposure to SARS-CoV-2, individuals who were boosted were less likely to have a registered positive test.

People with a previous registered positive test had lower likelihood of having a registered positive test in each period across both models. Unadjusted effect sizes were large. For example, between 1st September and 27th November 2021 (Delta) we estimated that individuals with had a previous registered positive test were 84% (testing engaged model HR = 0.16, 95% CIs = 0.15–0.18; Table 2) and 86% (healthcare engaged model HR = 0.14, 95% CIs = 0.13–0.16; Table 3) less likely to have tested positive than compared to those who had not. Associations were consistent following adjusting for other covariates. The unadjusted effect size was smaller in the Omicron period (testing engaged model HR = 0.73, 95% CIs = 0.71–0.76; healthcare engaged model HR = 0.58, 95% CIs = 0.56–0.60), although effect sizes strengthened upon adjustment. Sensitivity analyses suggested that these associations remained consistent following assessing if our measure was affected by immortal time bias (Additional file 1: Table C).

Table 3 Full model results for a Cox regression predicting time to a registered positive test for individuals who had received an influenza vaccination within a year of the time period start date (as a proxy for healthcare engaged)
Full size table

The associations for neighbourhood deprivation vary across each time period. In the first period (Delta—3rd June to 1st September 2021), we estimated positive associations in both models indicating that individuals in more deprived areas were more likely to have a registered positive test. To aid interpretation of this effect, we also estimated a model using national decile of deprivation (Additional file 1: Tables D and E). Individuals engaged in testing who resided in the least deprived decile were 24% less likely (HR = 0.76, 95% CIs = 0.72–0.81) and individuals who were healthcare engaged were 33% less likely (HR = 0.67, 95% CIs = 0.63–0.70), both compared to people in the most deprived decile.

In the second Delta period (1st September to 27th November 2021), the direction of the association was negative suggesting that as areas become more deprived, registered positive tests decreased. Individuals engaged in testing who resided in the least deprived decile were 37% more likely (HR = 1.37, 95% CIs = 1.30–1.44) and individuals who were healthcare engaged were 37% more likely (HR = 1.37, 95% CIs = 1.32–1.42), both compared to people in the most deprived decile (Additional file 1: Tables D and E). Age-stratified models suggest that the reversal of social inequalities appears to be driven by cases in children and older adults (Additional file 1: Figure A).

In the Omicron period (13th December 2021 to 28th February 2022), associations for deprivation showed diverging patterns across our models. Associations were positive in the testing engaged model (Table 2) and negative following adjustment in the healthcare engaged model (Table 3). This reflects the complexity in identifying associations over this period, where deprived and less deprived communities had the highest rates of registered positive tests at different points (Fig. 3). Initially incidence rates were higher in the least deprived decile, with trends reversing due to a larger peak of infections in the most deprived decile post-Christmas. By the end of the period, social inequalities had reversed again with more positive tests in the least deprived decile. For subsequent infections, the social gradient is more distinct with higher rates in the most deprived decile for most of the period before converging together (Fig. 2).

Fig. 3
figure 3

Comparison of seven day moving average for the number of residents in Cheshire and Merseyside per 100,000 people who registered a COVID-19 positive test for the most and least deprived deciles by whether it was an individual’s first registered positive test or a further/subsequent infection (3rd June 2021–2nd February 2022)

Full size image

Our results were broadly consistent when analysing all residents in Cheshire and Merseyside (Additional file 1: Table F). The only exception was for vaccination status in the Omicron period, where we found positive associations for all vaccination doses (although any interpretation should be made cautiously due to the level of bias in these data). Similarly, our results were broadly consistent when restricting the healthcare engaged individuals to only people aged 65 years and over (Additional file 1: Table G).

Discussion

Key results

Our study details the complex changes over time in who was affected by the COVID-19 pandemic. While number of cases were high during the Delta waves, Omicron saw unprecedented numbers of cases with 10.5% of people in Cheshire and Merseyside having a registered positive test. Subsequent infections were identified in 11% of these tests, with rates higher in deprived areas. The types of people with registered positive tests has changed widely. Initially, social inequalities were evident with registered positive tests higher in the most deprived areas. Since 1st September 2021, this has been less consistent with more registered positive tests in the least deprived areas (partly driven by patterns in children and adolescents). While there were fewer registered positive tests in vaccinated populations, this changed with Omicron. Finally, we find that people with a previous registered positive test were far less likely to have a subsequent registered positive test.

Interpretation

Our study does not assess vaccine effectiveness or vaccine impact on SARS-CoV-2 infection or COVID-19 disease. Rather it describes the types of people with registered positive tests for SARS-CoV-2 during the Delta and Omicron waves, and the complexity in being able to tease out these associations. Our analyses demonstrated that most new infections in the Delta wave occurred among unvaccinated populations. This association, however, becomes less clear with the emergence of Omicron where in individuals engaged in testing we observe more registered positive tests in individuals who were fully vaccinated (but not for those who were boosted or in individuals engaged with healthcare). This is not to suggest that being vaccinated places people at greater risk of being infected. Causal explanations for this association may include behavioural changes, such as increased physical contacts and working outside the home following vaccination increasing exposure to the virus [11, 12]. Evidence in England suggests that while individuals did not change behaviours after being vaccinated, increasing population vaccination levels were associated to changes in risk-compensatory behaviours and social contacts [26]. In addition, as most people get vaccinated or infected, the pool of unvaccinated people most susceptible to infection becomes smaller. It is plausible that this group is very different behaviourally and socially, and aversion to vaccination may translate to aversion to receiving or registering a test. For example, in the SIREN study where they test all individuals, they find fewer infections in vaccinated groups for each of our study periods [18], although the same study also has showed waning protection of vaccines in line with our findings [8]. Additionally, their analyses do not adjust for other covariates that may explain exposure to the virus. Finally, evidence has suggested that vaccines may have offered less protection to the Omicron variant due to immune escape [9, 27].

We find fewer registered positive tests in individuals with a previous positive test, with estimated effect sizes relatively larger than compared to vaccination status. This effect remains following adjusting demographic and social characteristics. The under-reporting of tests in individuals with a previous registered positive test may partly explain this difference. Immunity responses may also be different between vaccines and natural infections [6]. A large protective effect in natural infection has been reported elsewhere [8, 21]. Our estimated effect size reduced during the Omicron period, suggesting that the variant may be more effective at immune escape when compared to Delta. This is further highlighted by the larger percentage of subsequent infections identified.

Our findings should not be interpreted as naturally acquired immunity being recommended over vaccination. It is difficult to fairly compare effects across different variable types to identify which is most important and our methods do not allow for this. The people in our study who were previously infected excludes those that died of COVID-19, and the benefits of safe and effective vaccines have been clearly demonstrated in reducing COVID-19 hospitalisations and deaths [1, 4, 5]. However, our analyses might give some clues as to why England has not witnessed ‘herd immunity’ despite high levels of vaccination uptake.

From 1st September 2021, we found evidence of SARS-CoV-2 infections being higher in the least socioeconomically deprived communities. This remains in contrast to trends earlier in the pandemic, which had seen consistently higher infections in the most deprived areas [15], although not always [16]. The reversal of the social gradient in the Delta wave may be explained by several factors. One explanation may be the large protective effect of previous infections that we found. When combined with the concentration of infections in deprived areas in previous waves [15], this may have logically led to reduced population susceptibility to infections in more deprived communities during the Delta wave. When Omicron arrives it ‘resets’ these patterns since it is effectively a new serotype with immune escape [28], and the most deprived areas are affected more again. However, our analyses suggest that the reversal of the gradient was independent of previous infection and vaccination status of communities. A second explanation may regard the heterogeneity of social networks. The increasing socioeconomic segregation of who lives where [29] and school intakes [30], combined with low socioeconomic mixing and contact [31], may produce waves of infections that do not transfer between social groups and their closed networks. Our age stratified models suggest the reversal of social inequalities was strongest in children and adolescents, suggesting the importance of school dynamics in driving infections during Delta and Omicron [25]. Finally, inequalities in testing dynamics may produce an artefactual effect. Lower propensity to get tested or to register a test in deprived areas may bias our observations [32].

Limitations

There are limitations to our data source. CIPHA is based on all individuals registered with a GP. While this captures most people in the region, we do not have information for those individuals who are not registered which may introduce bias to our data. SARS-CoV-2 infections were identified based on a registered positive test. There was limited community testing availability during the first wave of infections and access to lateral flow tests were not available until late 2020 (6th November in Liverpool only, 3rd December rest of region). These issues may lead to missed infections that would not be reported in our data resulting in under-counts for previous positive tests. Not all individuals may get tested, nor register their test, leading to undercounts of infections in our measures. We do not know the extent of this under-reporting, including how it varies across our exposure variables, which may introduce selection bias. We attempted to account for some of these issues by restricting analyses to individuals who had registered a negative test in the month before due to established inequalities in testing uptake [32]. The impact of this can be seen by comparing the models to analyses for all residents (e.g., Table 2 and Additional file 1: Table F). We also report significant inequalities in who reported negative tests across our exposure variables (Additional file 1: Table A) which may bias underlying associations. The range of bias we are unable to observe shows how difficult it is to investigate these phenomena using routine data, so our results should not be over-interpreted.

Our analyses are descriptive and exploratory. We could not investigate the mechanisms that may underlie the associations we report (e.g., the processes that explain why social inequalities changed over time). We also are unable to account for all potential confounders or explanatory factors. For example, we did not have access to information matching individuals to households which may help to account for household transmission. It is plausible that our model adjustment may not be able to disentangle the association between demographic/social factors and our exposures (including risk behaviours and testing frequency). In particular, we only have access to area-level measures for socioeconomic deprivation which means any attempt to understand individual-level processes are at risk of the ecological fallacy. Future research should evaluate the potential reasons behind the relationships we describe, moving beyond the use of routine data to address some of the limitations of our analyses (e.g., social network analyses to study if the social segregation of communities explains inequalities flipping or using qualitative data to understand the contextual differences between poorer and affluent areas).

Conclusion

Using linked NHS and public health testing records for 2.7 M people in Cheshire and Merseyside, our study reveals the dynamic nature of SARS-CoV-2 infections through the Delta and Omicron waves. Socially patterned immunity by vaccination and prior infection resulted in social flips in who is infected, producing complex pictures of socioeconomic inequalities. Finding ways to effectively communicate the risks in exposure and infections among populations based on the changing dynamics we uncovered remains important. In the context of ‘living with COVID-19’ and the removal of most non-pharmaceutical interventions, our findings suggest that highly infectious SARS-CoV-2 variants will continue to spread unequally through society but not always in expected ways.

Availability of data and materials

Data are accessible via CIPHA (https://www.cipha.nhs.uk/). Requests can be made to the Data Access Committee for extracts of the larger-scale data which cannot be released openly due to information governance requirements. All analyses were undertaking using open source R statistical software and code is made openly available here https://github.com/markagreen/social_flip_COVID-19.

References

  1. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hartley G, Edwards E, Aui P, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5(54):eabf8891.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pattni K, Hungerford D, Adams S, Buchan I, Cheyne CP, García-Fiñana M, et al. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. BMC Infect Dis. 2022;22:270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. ONS. Deaths involving COVID-19 by vaccination status, England: deaths occurring between 2 January and 24 September 2021 [Internet]. 2021. Available from: https://www.ons.gov.uk/releases/deathsinvolvingcovid19byvaccinationstatusenglanddeathsoccurringbetween2januaryand24september2021.

  6. Baraniuk C. How long does covid-19 immunity last? BMJ. 2021;373.

  7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24): e85.

    Article  CAS  PubMed  Google Scholar 

  8. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386:1207–20.

    Article  CAS  PubMed  Google Scholar 

  9. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart ASV, Pollard AJ, et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399(10321):234–6.

    Article  CAS  PubMed  Google Scholar 

  10. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. West R, Michie S, Rubin GJ, Amlôt R. Applying principles of behaviour change to reduce SARS-CoV-2 transmission. Nat Hum Behav. 2020;4(5):451–9.

    Article  PubMed  Google Scholar 

  12. Smith LE, Mottershaw AL, Egan M, Waller J, Marteau TM, Rubin GJ. The impact of believing you have had COVID-19 on self-reported behaviour: cross-sectional survey. PLoS ONE. 2020;15(11): e0240399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Vilches TN, Jaberi-Douraki M, Moghadas SM. Risk of influenza infection with low vaccine effectiveness: the role of avoidance behaviour. Epidemiol Infect. 2019;147: e75.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Suleman M, Sonthalia S, Webb C, Tinson A, Kane M, Bunbury S, et al. Unequal pandemic, fairer recovery [Internet]. 2021. Available from: https://www.health.org.uk/publications/reports/unequal-pandemic-fairer-recovery.

  15. UK Government. Final report on progress to address COVID-19 health inequalities [Internet]. 2021. Available from: https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities.

  16. Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases: the impact of government policy in England. Soc Sci Med. 2021;289: 114413.

    Article  PubMed  PubMed Central  Google Scholar 

  17. ONS. COVID-19 vaccination rates and odds ratios by socio-demographic group [Internet]. 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/datasets/covid19vaccinationratesandoddsratiosbysociodemographicgroup.

  18. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. 2022. Available from: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings.

  19. Public Health England. Confirmed cases of COVID-19 variants identified in UK. 2021; Available from: https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-identified-in-uk.

  20. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med. 2018;6:121.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ministry of Housing Communities and Local Government. The English Indices of Deprivation 2019 [Internet]. 2019. Available from: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019.

  23. Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. N Engl J Med. 2021;385(15):1431–3.

    Article  CAS  PubMed  Google Scholar 

  24. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine [Internet]. 2013;31(48):5634–42.

    Article  PubMed  Google Scholar 

  25. Hughes DM, Bird SM, Cheyne CP, Ashton M, Campbell MC, García-Fiñana M, et al. Rapid antigen testing in COVID-19 management for school-aged children: an observational study in Cheshire and Merseyside, UK. J Public Health (Bangkok). 2022;fdac003.

  26. Buckell J, Jones J, Matthews PC, Diamond SI, Rourke E, Studley R, et al. COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK. medRxiv [Internet]. 2021; Available from: http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266255.abstract.

  27. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B11529) variant. N Engl J Med. 2022;386(16):1532–46.

    Article  CAS  PubMed  Google Scholar 

  28. Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? Nat Rev Microbiol. 2022;20:187–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dorling D, Rees P. A nation still dividing: the British census and social polarisation 1971–2001. Environ Plan A. 2003;35:1287–313.

    Article  Google Scholar 

  30. Gorard S. The complex determinants of school intake characteristics and segregation, England 1989 to 2014, Cambridge. J Educ. 2016;46(1):131–46.

    Google Scholar 

  31. Bridgen J, Jewell C, Read J. Social mixing patterns in the UK following the relaxation of COVID-19 pandemic restrictions: a cross-sectional online survey. medRxiv. 2021. https://doi.org/10.1101/2021.10.22.21265371v1.

    Article  Google Scholar 

  32. Green MA, Garcia-Fiñana M, Barr B, Burnside G, Cheyne CP, Hughes D, et al. Evaluating social and spatial inequalities of large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: an observational study of Liverpool, UK (November 2020 to January 2021). Lancet Reg Heal Eur. 2021;6: 100107.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the CIPHA team for their hard work in developing and maintaining their data resource.

Funding

This work was supported by the Medical Research Council [grant number MR/W021242/1], UKRI Innovation Fellowship [MR/R024847/1], the Department of Health and Social Care (DHSC), the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Gastrointestinal Infections, a partnership between UK Health Security Agency (UKHSA), the University of Liverpool and the University of Warwick [Grant No: NIHR ref NIHR200910] and the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between UKHSA, the University of Liverpool in collaboration with the Liverpool School of Tropical Medicine and the University of Oxford [Grant No: NIHR ref NIHR200907]. The views expressed are those of the authors and not necessarily those of the NIHR, UKHSA or DHSC. The funding sources had no roles in the design of the study or the decision to submit the paper for publication.

Author information

Authors and Affiliations

  1. Department of Geography and Planning, University of Liverpool, Liverpool, UK

    Mark A. Green & Alex Singleton

  2. Centre for Global Vaccine Research, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK

    Daniel J. Hungerford, Lance Turtle & Malcolm G. Semple

  3. NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, L69 7BE, UK

    Daniel J. Hungerford & Iain Buchan

  4. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, L69 7BE, UK

    Daniel J. Hungerford & Lance Turtle

  5. Department of Health Data Science, University of Liverpool, Liverpool, UK

    David M. Hughes, Marta Garcia-Fiñana & Christopher Cheyne

  6. Public Health, Liverpool Local Authority, Liverpool, UK

    Matthew Ashton

  7. Civic Data Cooperative, University of Liverpool, Liverpool, UK

    Gary Leeming & Iain Buchan

  8. Department of Public Health and Policy, University of Liverpool, Liverpool, UK

    Iain Buchan

Authors
  1. Mark A. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Hungerford
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David M. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marta Garcia-Fiñana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lance Turtle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christopher Cheyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthew Ashton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gary Leeming
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Malcolm G. Semple
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alex Singleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Iain Buchan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MAG, MGF and IB came up with the idea for the study. Study design was then refined by all authors. MAG, DMH and CC accessed the data, cleaned and prepared it for analysis. Analyses were led by MAG, with input from DJH, DMH, and MGF. MAG, DJH, DMH, MGF, LT and IB led on initially drafting the paper, with CC, GL, MA, AS and MS providing input on revising the paper. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Mark A. Green.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was granted by the University of Liverpool’s Research Ethics committee (REF: 10634). Data access was granted by the CIPHA Information Governance panel and Liverpool Clinical Commissioning Group as part of the COVID-19 response work the team were involved in. All data accessed were pseudo-anonymised prior to use.

Consent for publication

Not applicable.

Competing interests

IB declares grants from NIHR, personal fees and other from AstraZeneca, outside the submitted work. MGS declares non-remunerated participation on Pfizer’s External Data Monitoring Committee for their mRNA vaccine programmes. MGS holds stocks in Integrum Scientific LLC and MedEx Solutions Ltd. MGS also declares being a non-remunerated independent member of the UK Government’s SAGE and NERVTAG groups. No further conflicts of interest are declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Additional results and sensitivity analyses that supplement the core paper and are referred to in text.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Green, M.A., Hungerford, D.J., Hughes, D.M. et al. Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people. BMC Infect Dis 22, 889 (2022). https://doi.org/10.1186/s12879-022-07878-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-022-07878-2

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us